It shows herein more inflammatory with the antigen presenting cell that Bu Luomo structural domain inhibitor is handled, shows the relatively low expression of immunosuppression molecule PDL1, and the reactivity of tolerogenic T-cells can be restored. Therefore, disclosed herein are the method for promoting T cell activation during the cancer immunotherapy of subject, it is related to applying the composition comprising Bu Luomo structural domains inhibitor to the subject for receiving cancer immunotherapy. In addition also disclosed herein are a kind of methods for treating subjects cancer, including Bu Luomo structural domains inhibitor and immunostimulant is co-administered to subject.
